Dose escalation for salvage radiation therapy

In the late 1990s and early 2000s, the advent of more accurate linear accelerators (LINACs) and image-guidance technology for delivering therapeutic X-rays to the prostate in the treatment of prostate cancer changed the dose that could be safely given. … READ MORE …

How NOT to give salvage radiation after primary radiation failure

Recently, we commented on a couple of small studies where radiation re-treatment was used effectively and with acceptable toxicity. … READ MORE …

Safety limits of SBRT dose escalation

In a recent commentary, we saw that the lack of a standard of care for stereotactic body radiation therapy (SBRT) dose escalation may put patients at risk when dose limits are pushed beyond what is customarily considered effective and safe. … READ MORE …

Is there an optimal treatment schedule for high-dose-rate brachytherapy?

Protocols for high-dose-rate brachytherapy (HDR-BT) monotherapy vary. In recent years, practitioners have adopted various schedules for patient and physician convenience. … READ MORE …

Dose-escalated radiation therapy doesn’t impact survival within 10 years

Zaorsky et al. conducted a meta-analysis of 12 randomized clinical trials covering data on 6,884 patients treated with external beam radiation at various dose levels. … READ MORE …

Survival benefit of dose escalation for higher risk patients

As discussed in a previous article, there is a seeming discrepancy between the findings of Kalbasi et al. and RTOG 0126, at least for intermediate-risk patients. … READ MORE …

Lower dosing of abiraterone acetate in treatment of elderly prostate cancer patients

A group of Italian clinicians and researchers have reported that low-dose abiraterone acetate along with very low-dose prednisone appears to be both effective and safe in the treatment of elderly patients between 85 and 93 years of age with castration-resistant prostate cancer (CRPC). … READ MORE …